The extraordinary impact of camptothecin and its derivatives on topoiomerase I in preclinical studies on nude mice points to anticancer potential that has not yet been fully realized and developed. The 1996 Academy conference research on the camptothecins launched major advances in the understanding camptothecin's mechanisms of action (see vol. 803); the development of new derivatives; and pointed to a second generation of camptothecin-based chemotherapies. This volume unfolds this potential in four areas: mechanisms of action for the natural compound and current derivatives; chemical possibilities of modifying camptothecin; novel derivatives; novel routes of administration that enhance camptothecin's lactone ring stability, which appears vitally important for maintaining anticancer activity in humans. The science of camptopthecin-based anticancer is balanced by clinical and pharmacology topics including drug resistance, new analogues, and potential therapies for premature asthma and for bone marrow.
This volume is out of print.